Tumor mutations predict HER2-targeted therapy resistance in primary HER2-positive breast cancer.

NPJ Breast Cancer · 2026 · PMC13079752 · PMID 41974716

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significancep = 0.066so close (0.05 < p ≤ 0.1)

showed a trendno p-value reported

Correlation of PIK3CA mutations with outcome Patients enrolled in the G3 trial who had tumours with PIK3CA mutations showed a trend towards worse invasive disease-free survival (iDFS) compared to those with PIK3CA wild-type tumours, although this difference did not reach statistical significance (HR 2.1 (95%CI 0.95–4.78); p = 0.066) (Fig. 4 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.